Status:
COMPLETED
Effect of Budesonide / Formoterol Combination in Repeated AMP Provocations
Lead Sponsor:
AstraZeneca
Conditions:
Asthma
Eligibility:
All Genders
18-55 years
Phase:
PHASE4
Brief Summary
The aim is to study whether the budesonide component within the budesonide/ formoterol combination inhaler has additive value in a model of "slow onset acute asthma" , namely three AMP provocation tes...
Eligibility Criteria
Inclusion
- asthma diagnosis according to ATS criteria,
- lung function (FEV1) above 60% of predicted,
- AMP-PC20 below 160 mg/ml with a documented fall in FEV1 of 30% in this provocation test
Exclusion
- having smoked \> 10 Pack-years,
- hypersensitivity to one of the study drugs,
- significant co-morbidity, pregnancy or lactating
Key Trial Info
Start Date :
April 1 2004
Trial Type :
INTERVENTIONAL
End Date :
November 1 2005
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00272753
Start Date
April 1 2004
End Date
November 1 2005
Last Update
June 1 2011
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Amsterdam, Netherlands
2
Research Site
Groningen, Netherlands